In the United States and the European Union,<unk>  is indicated for the treatment of disease-related splenomegaly or symptoms in adults with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythaemia-vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis. It is also indicated for the treatment of adults with polycythaemia vera who are resistant to or intolerant of hydroxyurea. In the United States,<unk>  is also indicated for the treatment of steroid-refractory acute graft-versus-host disease in people who are twelve years of age and older, and for the treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in people twelve years of age and older. In the United States,<unk>  cream is indicated for the topical treatment of mild to moderate atopic dermatitis (AD).
Ruxolitinib
Ibrutinib
Bosutinib
Imatinib
Ranibizumab
Abrocitinib
Ceritinib
Ponatinib